First PD-1 Inhibitor Approved for Melanoma

Evidence-Based Oncology, September 2014, Volume 20, Issue SP14

The long-awaited PD-1 inhibitor from Merck, pembrolizumab (Keytruda), was granted accelerated approval by the FDA. The approval grants patients with unresectable melanoma, who are non-responsive to other drugs, access to this immunotherapy,1 which could have a tremendous impact on the prognosis of the 76,100 new cases of melanoma estimated in 2014.2

“Keytruda is the sixth new melanoma treatment approved since 2011, a result of promising advances in melanoma research,” said Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Many of these treatments have different mechanisms of action and bring new options to patients with melanoma.”1

Keytruda is the first immunotherapy molecule in the pipeline—a checkpoint inhibitor—to be approved after ipilimumab (Yervoy; Bristol-Myers Squibb). Iplilimumab, a CTLA-4 inhibitor, has been used in the treatment of metastatic melanoma since 2011.3 Ipilimumab has since been evaluated in other indications, such as non-small cell lung cancer.

Keytruda is the first approved drug that blocks the PD-1 signaling pathway, which restricts the body’s immune system from attacking melanoma cells, and is intended for use following treatment with ipilimumab. For melanoma patients whose tumors express the BRAFV600 mutation, Keytruda is intended for use after treatment with ipilimumab and a BRAF inhibitor.1

The treatment was granted breakthrough therapy designation following preliminary clinical evidence that showed the drug may offer a substantial improvement over available therapies, which include ipilimumab, peginterferon alfa-2b, vemurafenib, dabrafenib, and trametinib. It also received priority review and orphan product designation. Priority review is granted to drugs that have the potential, at the time the application was submitted, to be a significant improvement in safety or effectiveness in the treatment of a serious condition.

Orphan product designation is given to drugs intended to treat rare diseases.1

The encouraging results with Keytruda resulted in the regimen being evaluated under the FDA’s accelerated approval program, which allows earlier patient access to promising new drugs even while confirmatory trials are ongoing, by using surrogate end points. Improved survival or disease-related symptoms with Keytruda have not yet been established.1

EBO

Meanwhile, Bristol-Myers Squibb and Ono Pharmaceutical Company filed a lawsuit against Merck arguing that Keytruda impinges on their patent for a method of harnessing the body’s immune system to fight cancer by blocking the PD-1 receptor. The lawsuit was filed on the same day as the market approval of Keytruda. Bristol-Myers Squibb and Ono already have a PD-1 inhibitor, nivolumab (Opdivo), approved in Japan. Nivolumab is expected to be submitted for approval to the FDA by the end of September 2014 for melanoma treatment, and by the end of the year for lung cancer.4 References

1. FDA approves Keytruda for advanced melanoma [press release]. Silver Spring, MD: FDA; September 4, 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm.

2. Melanoma. National Cancer Institute website. http://www.cancer.gov/cancertopics/types/melanoma. Accessed September 9, 2014.

3. FDA approves new treatment for a type of latestage skin cancer [press release]. Silver Spring, MD: FDA; March 25, 2011. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm1193237.htm.

4. Loftus P. Bristol-Myers, Ono sue Merck over cancer-drug patent. The Wall Street Journal. http://online.wsj.com/articles/bristolmyers-ono-suing-merck-over-cancer-drug-patent-1410101449. Published September 7, 2014. Accessed September 10, 2014.